Antibody Information

General Information of This Antibody

Antibody ID	ANI0IMQOT
Antibody Name	LR004
Antibody Type	Monoclonal antibody (mAb)
Antibody Subtype	Humanized IgG
Antigen Name	Epidermal growth factor receptor (EGFR)	Antigen Info

Each Antibody-drug Conjugate Related to This Antibody

Full Information of The Activity Data of The ADC(s) Related to This Antibody

LR004-Val-Cit-MMAE [Investigative]

ADC Info

Discovered Using Cell Line-derived Xenograft Model

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Tumor Growth Inhibition value (TGI)	≈ 100.00% (Day 52)	High EGFR expression (EGFR+++)
Method Description	For the tumor xenograft model, 5.0x10⁶ MDA-MB-468 cells or 3.0x10⁶ MDA-MB-231 cells were injected subcutaneously into the right flank of each 6 week-old female BALB/c nude mice. when the tumor volumes reached approximately 100 mm³ (approximately 8 days), the 24 mice were randomly divided into 4 groups (6 mice per group): control group, LR004 antibody group, LR004-VC-MMAE group, and doxorubicin (positive control) group, which were treated with PBS or different drugs (LR004 antibody 10 mg/kg, LR004-VC-MMAE 10 mg/kg, doxorubicin 2 mg/kg) every 5 days for 4 times through i.v. injections. Click to Show/Hide
In Vivo Model	Triple-negative breast cancer CDX model
In Vitro Model	Breast adenocarcinoma	MDA-MB-468 cells		CVCL_0419

References

Ref 1	Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer. Mil Med Res. 2021 Dec 9;8(1):63.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.